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Abstract Despite improvements in both diagnostic and ther-
apeutic strategies, the prognosis of oral squamous cell carci-
noma (OSCC) has not changed significantly over the last de-
cades. Prognosis of OSCC particularly depends on the pres-
ence of nodal metastasis in the neck. Therefore, proper deter-
mination of the nodal status is pivotal for appropriate treat-
ment. Unfortunately, current available imaging techniques
(magnetic resonance imaging or ultrasound even with fine
needle aspiration of suspected lymph nodes (LNs)) fail to
detect occult nodal disease accurately. Clinicians in head and
neck oncology urgently need new diagnostic tools to
reliably determine the presence of nodal metastasis of
the neck. Gain of the chromosomal region 11q13 is
one of the most prominent genetic alterations in head
and neck cancer and is associated with poor prognosis
and metastasis. The aim of this systematic review and
meta-analysis was to determine the diagnostic value of
either 11q13 amplification or amplification/protein over-
expression of individual genes located on 11q13 to de-
tect nodal metastasis in OSCC. A search was conducted
in Pubmed, EMBASE, and Cochrane, and 947 unique
citations were retrieved. Two researchers independently
screened all articles and only 18 were found to meet
our inclusion criteria and were considered of sufficient
quality for meta-analysis. Pooled results of those show
that both amplification of CCND1 and protein overex-
pression of cyclin D1 significantly correlate with lymph
node metastasis (LNM) in OSCC. In addition, amplifi-
cation of CCND1 shows a negative predictive value of
80 % in the detection of LNM in early stage OSCCs
which are clinically lymph node negative although this
evidence is sparse and should be validated in a larger
homogeneous cohort of T1-2 OSCC.
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Introduction
Head and neck cancer is a heterogeneous group of malignan-
cies and the sixth most common malignancy worldwide [1].
Approximately one third of all head and neck squamous cell
carcinoma (HNSCC) consists of oral squamous cell carcino-
ma (OSCC). Despite improvements in both diagnostic and
therapeutic strategies over the past decades, 5-year overall
survival rate has not improved significantly and remains poor
with on average 50–60 % [1, 2]. The prognosis of OSCC is
largely determined by the presence or absence of lymph nodal
metastasis (LNM). Therefore, proper determination of the
nodal status of the neck is pivotal. Unfortunately, current
available imaging techniques such as magnetic resonance im-
aging (MRI) or even ultrasound with fine needle aspiration of
suspected lymph nodes fail to detect the presence of nodal
metastasis accurately; 30 to 40 % of patients with clinically
lymph node negative neck have occult nodal metastasis and
will develop nodal disease if the neck is left untreated [3]. This
urges for better diagnostic tools to detect regional metastasis
more accurately. Ultimately, this will result in a better and a
more individualized treatment of the neck in patients with
OSCC.
To improve diagnostics of nodal status in OSCC, new tech-
niques such as molecular diagnosis and tumor profiling are
promising [3]. Amplifications and deletions of chromosomal
regions are genetic alterations and both driving forces in car-
cinogenesis of several malignancies [4]. Gain of the chromo-
somal region 11q13 has been established as one of the most
prominent (36 %) genetic alterations in head and neck cancer
and is associated with poor prognosis [5]. Recent research
identified 11q13.3 as the most frequently amplified gene
region: It contains several potential driver genes such as
CCND1, CTTN, FADD, FGF19, and ORAOV1 [6]. A re-
cent review with meta-analysis indicated that immunohis-
tochemical overexpression of cyclin D1 located on 11q13
(protein of gene CCND1) correlated both with the pres-
ence of nodal metastasis and a worse survival in an Asian
population with OSCC [7]. For amplification of CCND1
and amplification or overexpression of any of the other
genes located on chromosome 11q13.3, the diagnostic val-
ue in determining nodal metastasis in OSCC is unclear,
and no comprehensive review has been conducted yet.
The relationship between amplification or overexpression
of the 11q13 region or genes located on 11q13 and the
detection of LNM in primary OSCC has been explored,
and the number of papers is increasing rapidly. However,
none of these biomarkers is used in current clinical prac-
tice since study results are conflicting and results of ade-
quately designed translational studies are lacking [8–11].
Therefore, we conducted a systematic review and meta-
analyses if possible, of all studies performed to date, to define
the overall diagnostic value of 11q13.3 amplification or




We conducted a systematic search for original articles pub-
lished until the 30th of April 2014 in the Pubmed, EMBASE,
and Cochrane databases for original articles. Search terms
used were “oral cancer,” “11q13” (or individual genes located
on 11q13), and “metastasis” and their synonyms in title and
abstract fields; see Supplementary Table S1. All titles and
abstracts were independently screened by two authors (R.N.
and P.M.W.K.) using predefined inclusion and exclusion
criteria (see below). Subsequently, the full text of relevant
studies was screened for a more detailed selection. Discordant
judgments were resolved by consensus discussion. Reference
and citation check of selected articles was performed to iden-
tify potentially missed relevant studies.
Inclusion and exclusion criteria
For this review, full-text articles were selected on the basis of
(1) correlation of 11q13 overexpression or amplification with
(2) nodal metastasis in (3) patients with OSCC or HNSCC
with a subgroup of OSCC, with (4) clinical or histopatholog-
ical nodal status as reference standard.
Used exclusion criteria were (1) duplicate articles that
contained all or some of the original publication data, (2)
reviews, book chapters, cases reports, editorials, oral presen-
tations, technical notes, and poster presentations, (3) articles
which included head and neck cancer without a subgroup of
OSCCs, and (4) articles in a language other than English,
German, or Dutch.
Critical appraisal and data extraction
Quality assessment of included studies was performed by crit-
ical appraisal, based on standardized criteria for diagnostic
research using the QUADAS-2 tool for quality assessment
of diagnostic accuracy studies [12]. Risk of bias was scored
as low, high, or unknown (if the itemwas not mentioned in the
article) based on the following items:(1) patient selection—
consecutive cohort of patients, avoidance of case-control, and
avoidance of inappropriate exclusions; (2) index test—re-
searchers blinded to reference standard and pre-specified
threshold; (3) reference standard—validity of reference stan-
dard and blinding for the index test; and (4) flow and timing—
interval between and standardization of test and reference
standard, and completeness of data. In addition, the first three
items were also scored on applicability for this review: (1)
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patient selection—only OSCC included in study; (2) index
test—dichotomized outcome with cutoff point instead of con-
tinuous outcome and useful for review question; and (3) ref-
erence standard—either histological nodal status or follow-up
of an untreated neck for at least 2 years.
We extracted first author, year of publication, country, sam-
ple size, tumor location, TNM stage, distribution or average
age, used antibody, investigated genes/proteins, method, and
outcome from each study. Amplification or overexpression
and nodal metastasis data for crosstabs were extracted from
included studies. All studies with source data for a crosstab
available were included in the meta-analysis. In case of insuf-
ficient data, authors were contacted to provide the source data.
For complete and transparent reporting of the results of our
review, we used the preferred reporting items for systematic
reviews and meta-analyses (PRISMA) statement checklist
[13].
Statistical analysis
Odds ratios (ORs) were used to describe the correlation be-
tween 11q13 amplification or overexpression of its genes and
nodal metastasis. Negative predictive value (NPV), positive
predictive value (PPV), accuracy, sensitivity, and specificity
were calculated from extracted crosstabs using the EPR-Val
Toolkit Version 2 [14]. If insufficient data were available, for
example, if only the p value mentioned in the included article
was published, the study was excluded from further meta-
analysis.
For meta-analysis, the conservative random effect model
was used to calculate the pooled estimates, and statistical sig-
nificance was determined using the Z-test [15]. Test for het-
erogeneity across studies was performed using both Q test and
the Higgins I2. The Higgins I2 describes the proportion of
inter-study variability in effect estimates that is due to hetero-
geneity rather than sampling error (change) and ranges from 0
to 100 %. Although distinct values are arbitrary since more
factors influence heterogeneity, I2 values of 0, 25, 50, and
75 % are indicated as “no,” or a “low,” “moderate,” and
“high” amount of heterogeneity [16, 17]. All statistical tests
for meta-analyses were performed using Comprehensive
Meta-Analysis 2.0 software (Biostat, Englewood, NJ), and p-




Our search resulted in 1303 citations, 759 from PubMed and
544 from the EMBASE database. After removal of duplicates,
947 unique citations remained for screening on title and
abstract. After both title and abstract screening and full text
screening, original research papers were included for critical
appraisal. Three (Myo, Miyamoto, and Michikawa) articles
from the same institute with partly overlapping inclusion data
were included [9, 18, 19]. Michikawa et al. [19] was the most
recent article with the largest group of patients in which de-
tection of CCND1 amplification was performed in relation to
LNM; however, Myo et al. [9] was the only study that per-
formed a subanalysis in the clinically most relevant group of
early OSCCs which were clinically lymph node negative.
Therefore, we decided to include both studies in our review.
Additionally, Miyamoto et al. was the only study who per-
formed protein expression analysis of cyclin D1 next to
CCND1 amplification in this cohort. Therefore, we decided
to solely include the protein expression analyses of this study
in our review and meta-analysis [18]. Reference and citation
check revealed two additional papers which met our inclusion
criteria; see flowchart in Fig. 1. These studies were not includ-
ed in our initial search because the study of Yoshioka et al.
[20] did not mention 11q13 or any of the individual genes in
the tile or abstract and the study of Takahashi et al. [21] was
not indexed in PubMed or EMBASE. However, Takahashi
et al. [21] might have reported overlapping data with
Michikawa et al. [19] as the enrolment periods overlap




- PubMed (n = 759)
- EMBASE (n = 544)
- Cochrane (n = 0)
Studies screened on title
and abstract (n = 947)
Studies screened on
full text (n = 160)






Studies excluded (n = 112)
- No full text (5)
- Language* (8)
- No OSCC (16)
- Lack of outcomes (62)
- No original studies (21)
Reference and citation
check (n = 2)
Fig. 1 Flowchart search. * Languages: Chinese (4), Polish (2), Japanese
(1) and Spanish (1)
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Table 1 Quality assessment of studies included















2012 Huang + + + + Low risk + + + Applicable
for review2011 Sugahara + + + + + + +
2011 Pathare + + + + + + +
2011 Michikawaa + + + + + + +
2011 Mahdey + + + + + + +
2009 Shah + + + + + + +
2005 Myoa + + + + + + +
2003 Miyamotoa + + + + + + +
2002 Takes + + + + + + +
2014 Hanken + + + − Moderate risk + + +
2013 Yoshioka − + + + + + +
2010 Prapinjumrune + − + + + + +
2007 Maahs + ? + + + + +
2005 Rodolico + + + − + + +
2002 Goto ? + + + + + +
2001 Fujii + + + − + + +
1999 Bova − + + + + + +
1999 Kuo + ? + + + + +
2013 Pattje + + + + Low risk − + + Not applicable
for review2004 Do + + + + − + +
2000 Rodrigo + + + + − + +
1997 Mullera + + + + − + +
1997 Fortin + + + + − + +
2013 Fan − + + + Moderate risk − + +
2013 Li + + ? + + + ?
2012 Rasamny + + − + − + −
2011 Das + + ? + + + ?
2006 Wang + + ? + + + ?
2005 Shiraki + + − + + + −
2005 Soni + + − + + + −
2003 Vora + + ? + − + ?
2000 Capaccio − + + + − + +
2000 Mineta + + −b + + + −
1997 Kyomoto + + − + − + −
1994 Mullera − + + + − + +
1994 Parise ? + + + − + +
2014 Pickhard + ? + ? High risk − − +
2013 Zhong + + − − + + −
2010 Yamada − + ? + + + ?
2009 Liu − + ? − + + ?
2007 Xia − + ? + + + ?
2006 Zhou − − + + + − +
2004 Liu ? + − + + + −
2004 Chen − + ? − + + ?
2002 de Vicente − + ? + + + ?
2002 Namazie − + ? − − + ?
1999 Alavi + + ? ? − + ?
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Critical appraisal
All 50 studies that were selected for further analysis were
appraised by the QUADAS-2 tool for quality assessment of
diagnostic accuracy studies. They were scored on risk of bias
and applicability for this review; see Table 1. Eighteen studies
were found of sufficient applicability with respect to our re-
view question [8–11, 18–33]. Nine of these studies scored all
four items as low risk of bias and the other nine scored three
out of four items as low risk of bias. According to the
QUADAS-2 tool, the quality of these 18 articles was good
or moderate, and they were included for result analysis. Nine
of the included studies investigated the correlation between
gene amplification and nodal metastasis; ten studied the cor-
relation between protein overexpression and nodal metastasis;
see Table 2. From 32 excluded studies, 18 studies scored
moderate (three out of four items, low risk) or good (all four
items, low risk) quality with respect to risk of bias. The main
reasons for insufficient applicability of these studies were (1)
inclusion of other head and neck subsites than oral cavity
without subgroup analysis and/or (2) clinical nodal status in-
stead of histologically proven nodal metastasis or adequate
follow-up as reference standard. Fourteen studies scored bad
(one or two items, low risk) on risk of bias and applicability
and therefore were excluded from further analysis.
Study characteristics
In total, the selected 18 studies comprised a total of 1646
patients (range, 23–264 patients); 736 patients were included
in studies correlating gene amplification with nodal status and
970 patients in studies correlating protein overexpression with
nodal status. Thirteen studies were performed in Asia, three in
Europe, one in Australia, and one in Brazil. Most studies in-
cluded all stages of OSCC, but three studies looked specifi-
cally at early (stage I–II) cancers of which the study of Myo
et al. investigated the clinically most relevant group of early
OSCCs which were clinically lymph node negative [9, 26,
29]. The differences in selected study population resulted in
a wide range of prevalence of histologically proven nodal
metastasis (13 to 63 %). In the studies investigating the diag-
nostic value of gene amplification for the detection of nodal
metastasis, five articles studied the diagnostic accuracy of
CCND1 amplification using fluorescence in situ hybridization
(FISH) for the detection of LNM [9, 11, 19, 22, 25]. Three
studies looked at amplification of 11q13 region using the com-
bination of multiple genes with comparative genomic hybrid-
ization (CGH) [20, 23, 24], and one study looked at amplifi-
cation of FADD using RT-PCR [26]. Besides different detec-
tion methods, also several definitions of amplification were
used among these studies. In the studies investigating the di-
agnostic accuracy of protein overexpression of genes located
at 11q13 in detection of nodal metastasis, nine articles studied
immunohistochemistry (IHC) of cyclin D1 and one study of
FADD [8, 10, 26–33]. Half of the studies used 10% staining as
cutoff value for overexpression, three studies had lower, and
two studies had higher cutoff points. Most studies used a pre-
specified cutoff; only Prapinjumrune et al. established overex-
pression as expression in the top two thirds of the study cohort
(>29.2 %) [26]. Study characteristics are summarized in
Table 2.
Diagnostic value of 11q13 amplification region or individual
genes located on 11q13 in detection of nodal metastasis
Table 3 shows the diagnostic accuracy of all studies correlat-
ing gene amplification of 11q13 region and nodal metastasis.
Besides a wide range in prevalence of histologically proven
nodal metastasis, the nine studies showed a wide range in the
detected amount of amplification (26 to 72 %). Three studies
showed a statistically significant correlation between amplifi-
cation of 11q13 (or individual genes) and the presence of
nodal metastasis in OSCC [9, 19, 23]. However, the other
six studies did not find a correlation between amplification
and nodal metastasis. The NPV ranged from 30 to 83 % and
the PPV from 38 to 80 %. With a threshold of ≥3 spots of
CCND1 in >20 % of 100 cells under the microscope, a com-
monly used threshold in FISH, Myo et al. [9] found the best
Table 1 (continued)















1995 Meredith ? ? ? − − − ?
1995 Rubin ? + ? + + + ?
1994 Volling ? ? ? + − ? ?
Legend: +, low risk; −, high risk; ?, unclear. “Unclear” was seen as high risk of bias for determining the quality of a paper
a Studies with overlapping patient inclusion
b Corresponding author contacted, used CT/MRI as reference standard
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accuracy (82 %) and was also the only study investigating
nodal metastasis in a cohort of clinically nodal negative early
OSCC (cT1-2N0). Meta-analysis of the five studies correlat-
ing CCND1 amplification by FISH with nodal metastasis re-
vealed a statistically significant increase in risk of nodal me-
tastasis with an odds ratio of 2.12 (95 % confidence interval
(CI) 1.43–3.16), with moderate risk of heterogeneity (I2=65)
[9, 11, 19, 22, 25]. Meta-analysis of the three studies correlat-
ing 11q13 amplification by CGH with nodal metastasis
showed no statistically significant correlation (odds ratio
2.00 with 95 % CI 0.77–5.21), with moderate risk of hetero-
geneity (I2=46) [20, 23, 24]. The results are presented in for-
ests plots in Fig. 1, and the tests of heterogeneity are shown in
Table 5.
Diagnostic value of 11q13 overexpression in detection
of nodal metastasis
Table 4 shows the diagnostic accuracy of all studies correlat-
ing protein overexpression of genes located on 11q13 and
nodal metastasis. Most studies correlated immunohistochem-
ical expression of cyclin D1 with nodal metastasis, except
Prapinjumrune et al. who looked at FADD expression [26].
The amount of overexpression of cyclin D1 varied from 32 to
83 %. Two studies showed a significant correlation between
cyclin D1 overexpression and nodal metastasis in OSCC [8,
32], Goto et al. [30] found a trend toward more metastasis in
tumors with overexpression, and the other six studies found
no correlation at all. The NPV ranged from 32 to 73 % and the
PPV from 37 to 85%. The diagnostic accuracy ofmost studies
was poor, the best being 66 % in the study of Goto et al. [30]
Prapinjumrune et al. also found a significant correlation be-
tween FADD expression and nodal metastasis, with a NPVof
44 % and a PPV of 83 % [26]. Two articles had insufficient
data for meta-analyses [22, 29]. Although these authors were
contacted by e-mail, these data were not provided.
Meta-analysis of the seven studies correlating cyclin D1
overexpression by immunohistochemistry (IHC) with the
presence of nodal metastasis revealed a statistically significant
increase in risk of nodal metastasis with an odds ratio of 1.95
(95 % CI 1.40–2.70), with low risk of heterogeneity (I2=1) [8,
10, 27, 28, 30–33]. See also forest plot and test of heteroge-
neity in Fig. 2 and Table 5.
Discussion
New diagnostic biomarkers to improve the diagnosis of nodal
metastasis in patients with OSCC are pivotal for a better and
more individualized treatment of the neck [3]. Amplification
of 11q13 is common in head and neck cancer, and several
studies showed a correlation with metastasis and poor surviv-
al. However, results vary between studies, and no coherent
review has been performed at present with regard to the diag-
nostic value of 11q13 amplification, amplification of individ-
ual genes located on 11q13, or overexpression of its genes in
the detection of nodal metastasis from oral cancer. Little is
known about the NPVof these alterations, which is the most
important diagnostic value to safely omit an elective treatment
of the neck in patients with early OSCCO. Overall, the results
of our meta-analysis show that both amplification of CCND1
and overexpression of cyclin D1 correlate with nodal metas-
tasis in OSCC. Furthermore, CCND1 amplification seems to
have great potential as a diagnostic biomarker for lymph node
metastasis in a subgroup of clinically nodal negative OSCC
although supporting evidence is still not very strong.
The strength of a systematic review depends on the quality
of the search, critical appraisal, and reporting of the review.
For selection of studies, we used the validated QUADAS-2
Table 3 Diagnostic accuracy of 11q13 amplification for nodal status in OSCC
Study Nodal
metastasisa







Hanken et al. 117/255, 46 % G/C ratio >2.0 69/255, 27 % 1.66 (0.95–2.90) 0.074 57 55 57 32 77
Yoshioka et al. 15/25, 60 % G/C ratio >1.12 13/25, 52 % 1.14 (0.23–5.67) 0.870 42 62 52 53 50
Sugahara et al. 22/54, 41 % G/C ratio >1.5 in ≥3 genes 14/54, 26 % 5.83 (1.52–22.33) 0.010 70 71 70 45 88
Pathare et al. 54/97, 56 % G/C ratio >1.25 40/97, 41 % 1.35 (0.60–3.06) 0.473 47 60 53 44 63
Michikawa et al. 53/127, 42 % G/C ratio >1.2 and gene/cell ratio >3 43/127, 34 % 2.78 (1.30–5.92) 0.008 67 58 64 47 76
Mahdey et al. 27/50, 54 % G/C ratio >2.0 36/50, 72 % 1.87 (0.54–6.51) 0.327 57 58 58 78 35
Prapinjumrune et al. 13/30, 43 % G/C ratio >1.5 13/30, 43 % 0.70 (0.16–3.05) 0.638 53 38 47 38 53
Myo et al. 17/45, 38 % >20 % of 100 cells ≥3 spots 15/45, 33 % 20 (4.09–97.90) <0.001 83 80 82 71 89
Fujii et al. 14/23, 61 % >20 % of 100 cells ≥3 spots 13/23, 57 % 0.50 (0.09–2.84) 0.434 30 54 43 50 33
OR odds ratio, CI confidence interval, G/C gene/chromosome, NPV negative predictive value, PPV positive predictive value, AC accuracy, SE
sensitivity, SP specificity
a Histologically proven nodal metastasis
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tool to judge their quality [12]. The first finding in this critical
appraisal was the large number of studies which included
patients with head and neck cancer originating from different
subsites, or used clinical nodal status as reference standard
instead of histologically proven metastasis. Discrimination
of head and neck subsites is particularly relevant, because
multiple studies show differences in genetic alterations, such
as mutations, amplification, or deletions, between its different
subsites [34–36]. As a consequence, the effects of amplifica-
tion of 11q13 in any other location of the head and neck than
the oral cavity cannot be extrapolated to OSCC. For this rea-
son, we excluded all studies which included tumors other than
OSCC and all studies without a separate location analysis. As
mentioned earlier, the determination of nodal metastasis with
imaging modalities is inaccurate in OSCC. Therefore, we ex-
cluded all studies using another reference standard than either
histologically proven nodal metastasis or follow-up of the
neck for at least 2 years [3].
Despite the fact that all studies analyzed included only
OSCC and used histologically proven nodal metastasis as a
reference standard, the correlation and diagnostic accuracy
between amplification of the 11q13 region as well as overex-
pression of cyclin D1 and LNM still varied among the includ-
ed studies. There are several possible explanations for these
differences: First of all, there is heterogeneity in the stages of
the includedOSCCs.Most studies included all different stages
of OSCC and three studies included only early stage OSCC
[9, 26, 29]. Since early stages of OSCC show less genetic
alterations than late stage OSCC, this could explain the stron-
ger correlation in these three studies focused on stage 1–2
OSCC compared with the more variable correlation in studies
that included all stages of OSCC [36]. Although Hanken et al.
[22] found no significant differences in CCND1 amplification
between T1-2 and T3-4 OSCC, this study did not look at the
correlation of CCND1 amplification and LNM in these sub-
groups. Second, differences in methodological setup might
explain part of the differences as the used assays, explored
genes, and cutoff point for amplification varied between the
12 amplification studies. Although most protein expression
studies used the same methods and explored the same genes
(IHC for cyclin D1), these studies used different primary an-
tibodies (see Table 4) and there was a wide range in the def-
inition for overexpression (1–33 %) [8, 10, 27–33]. Third,
geographical or ethnical differences may account for a differ-
ent outcome. Sixteen of the included studies were carried out
in Asians, three in Caucasians, and one in an ethnically mixed
group, although no divergent results were observed in out-
come, which is in line with an earlier review [7]. Finally,
one has to realize that OSCC includes tumors arising from
different oral cavity subsites such as the cheek, floor of the
mouth, and oral tongue. Meanwhile, an increasing number of
studies have appeared that show differences in molecular bi-
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This meta-analysis shows a significant correlation between
both cyclin D1 protein overexpression as well as CCND1
amplification by FISH and the detection of nodal metastasis
in OSCC. It is noteworthy that the strength of correlation
between CCND1 amplification and the detection of LNM
might be influenced by possible overlapping data in two in-
cluded studies [9, 19]. Furthermore, a recent review in an
Asian population by Zhao et al. found a slightly stronger cor-
relation between cyclin D1 overexpression and nodal metas-
tasis. However, they used a fixed-model method in their meta-
analyses and also included studies using clinical nodal status
as reference standard [7]. In order to use the fixed-model
method, two conditions have to be fulfilled: (1) There must
be good reasons to believe that all studies are functionally
identical and (2) the computed effect cannot be generalized
beyond the population included in the analysis. Although the
Q-test for heterogeneity was not significant for cyclin D1
overexpression, we believe that the included studies are not
functionally identical due to above mentioned differences in
materials and methods, and therefore, we applied the more
conservative random-model method. This model allows dif-
ferences in effect size between studies and therefore leads to
wider confidence intervals, especially if only few studies are
included in the meta-analysis [15].
Meta-analysis of 11q13 amplification by CGH showed no
significant correlation with nodal metastasis, which may seem
contradictory to the other results. This inconsistency may be
explained as follows: First of all, two studies (Yoshioka et al.
and Pathare et al.) used relatively low cutoff values for ampli-
fication compared with the other CGH study and the FISH
studies; see Table 2. Second, the total sample size of this
meta-analysis was small and included only 176 patients,
Fig. 2 Meta-analyses of (A)
CCND1 amplification, (B) 11q13
amplification and (C) cyclin D1
overexpression and nodal
metastasis using random-model
method with Odds Ratio’s and
95 % CI in figures
Table 5 Heterogeneity in meta-analysis
Meta-analysis Q-value df (Q) p value I2
Cyclin D1 overexpression (IHC) 7.086 7 0.420 1.212
CCND1 amplification (FISH) 11.597 4 0.021 65.509
11q13 amplification (CGH) 3.727 2 0.155 46.341
IHC immunohistochemistry, FISH fluorescence in situ hybridization,
CGH comparative genomic hybridization
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compared with 500 patients in the CCND1 amplification by
FISH analysis and 813 patients in the cyclin D1 overexpres-
sion analysis; see Fig. 2.
For potential use as diagnostic tool in clinical decision
making, the NPV of a biomarker in clinically lymph node
negative OSCC is even more important than an overall corre-
lation, since false negative results have serious consequences
for the patient [37]. Unfortunately, only two studies (Myo
et al. and Rodolico et al.) investigated the role of CCND1
amplification or cyclin D1 protein overexpression in this spe-
cific subgroup, both with a significant correlation with nodal
metastasis [9, 30]. Of these studies, only Myo et al. reported
sufficient data to reliably extract the NPV (83 %) and PPV
(80 %). These results are promising considering the pre-test
probability of 38 % for a nodal metastasis but need further
validation in a larger cohort. The source data of the other study
unfortunately could not be obtained from contacted authors.
Although we performed a comprehensive and systematic
review with transparent methods, quality check, and extrac-
tion of study results, several limitations have to be mentioned.
First, the search for this review was restricted to studies pub-
lished in English, German, and Dutch, which after quality
check led to inclusion of 20 articles (8 articles were excluded
because of the language). In comparison with the review by
Zhao et al., we could have missed some articles written in
Chinese [7]. Second, because of the known inconsistence be-
tween clinically and histologically proven nodal metastasis,
we only included studies that explicitly mentioned
“pathological” or “histological” nodal metastasis in their
manuscript and we left out three articles of moderate/
good quality on risk on bias (at least three out of four
items, low risk; see Table 1) that were unclear about
their reference standard for nodal status. Although the
likelihood of introduction of bias was minimized, poten-
tially relevant studies could have been omitted from this
analysis. Third, all presented studies are based on anal-
ysis of resection specimen. To be of diagnostic value
for daily clinical practice, it would be relevant to vali-
date these findings for incisional biopsies as well. Fi-
nally, we did not stratify our meta-analyses for anatom-
ical subsites in the oral cavity. This may have to be
taken into account in future analysis since evidence is
increasing that these different locations might show dif-
ferent molecular alterations during carcinogensis [25].
In conclusion, according to current available evidence,
both amplification of CCND1 and overexpression of cyclin
D1 are potential biomarkers in the detection of LNM in
OSCC. For early stage OSCC, which is the clinically most
relevant subgroup, amplification of CCND1 had a NPV of
83 %. However, this evidence is based on only one study,
and these results will have to be validated in a larger cohort
of early OSCC, with subsite analysis. If these results confirm
an association between CCND1 or 11q13 amplification and
the presence of occult nodal disease in less than 20 %of the
patients, this biomarker is of additional value in deciding as to
whether or not treat the neck at early stage OSCC.
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